Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. by Blackledge, G. et al.
Br. J. Cancer (1989), 59, 650-653 © The Macmillan Press Ltd.,
Response of patients in phase II studies of chemotherapy in ovarian
cancer: implications for patient treatment and the design of phase II
trials
G. Blackledge, F. Lawton, C. Redman & K. Kelly
West Midlands Cancer Research Campaign Clinical Trials Unit, University of Birmingham, UK.
Summary Results using the same drug in phase II studies of treatment in ovarian cancer vary widely. An
analysis of five phase II studies with a total of 93 patients was carried out to determine whether factors other
than the efficacy of the drug affect response. The drugs for the phase II studies were chosen on the basis of in
vitro activity or previous activity in humans. Univariate analysis showed that several factors were of
significance in predicting response. The most significant was interval from the end of previous treatment to
entry into a phase II study. Others were the original presenting stage of the patient, the second line treatment
given and the best previous response to therapy. In multivariate analysis, however, only two factors were
shown to be of importance which were interval and the FIGO stage of the patient. Using these two variables
the discriminant analysis predicted 89% of those who did not respond and 75% of those who did, with an
overall correct prediction of 85%. The importance of interval is emphasised by the observation that the
response rate for those patients who progressed on treatment or who relapsed within 3-6 months of primary
therapy had a response rate of <10%. Future phase II studies should probably exclude patients in this
category, since the chance of their responding is very low.
The outlook for patients suffering from advanced ovarian
cancer is poor, with fewer than 20% of patients with stage 3
or stage4 disease surviving more than 5 years (Katz et al.,
1981). The disease is sensitive to chemotherapy but in
advanced disease the role of chemotherapy is palliation in
the majority of patients (Neijt et al., 1986).
Since the majority of patients will respond to established
chemotherapy agents, it is difficult ethically to evaluate new
agents as first line treatment. Evaluation of new agents is
confined to patients relapsing or progressing at the end of
primary therapy. Studies of a wide range of chemo-
therapeutic agents have shown widely varying results (Ozols
& Young, 1984). In studies of cisplatinum, for example,
response rates in the range of 15-50% have been observed
(Thigpen & Blessing, 1985) and in evaluations of the anthra-
cenedione mitoxantrone response rates from 0 to 28% have
been seen (Lawton et al., 1978a; Muss et al., 1984; Hilgers et
al., 1984).
Such variations in response rates suggest that factors other
than the activity of the drug may be involved in determining
whether a patient is likely to show response to a new drug.
This has implications for the evaluation of new drugs, and
may explain why some studies have failed to detect active
drugs.
In an attempt to identify whether such factors exist we
have examined retrospectively a group of patients from this
centre treated in a number of phase II studies over a period
of 4 years. We have aimed to identify factors which predict
patients who will respond to chemotherapy.
Patients and methods
A total of 92 patients were entered into five phase II
chemotherapy trials from 1983 to 1987 (Lawton et al., 1985,
1986, 1987a, b; Redman et al., 1988). These studies had
common entry criteria; patients had biopsy proven epithelial
ovarian carcinoma, had received at least first line treatment
and had either progressed on or relapsed after therapy.
Patients, though symptomatic, were medically fit to receive
treatment and has an anticipated life span in excess of 2
months. Patients had WHO performance status of 0 or 1.
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Response was assessed using standard UICC criteria. The
treatments being evaluated were selected on the basis of in
vitro cytotoxicity data, and previous single agent phase II
data. The number of patients in each of the phaseII trials
and the characteristics of the responding and non-responding
patients are shown in Table I.
The significance of differences between the responders and
non-responders in age and in the interval from the cessation
of previous treatment to the phaseII treatment was tested
using the Mann-Whitney U test. Differences in the
discontinuous variables were tested by calculating x2 from
the two way contingency tables.
The variables used in a discriminant function analysis to
determine the best combination of characteristics for
classifying patients into responders and non-responders are
shown in Table II. A number of transformtions of age and
interval were assessed. The computer package of Biomedical
Programs (BMDP) was used for these analyses.
Patient classifications based on the best discriminant
function were compared with observed response to phase II
treatment.
Results
The univariate analysis suggested that patients who
responded in phase II studies had a longer interval from
completing prior therapy to entering the phase II study, had
less advanced disease at initial presentation, and had disease
that had previously responded to prior treatment. The type
of phase II regimen also influenced the number of responses
seen, with the combinations including cis-platinum having a
higher response rate.
In the discriminant analysis, the interval from the end of
prior treatment to entering a phase II study was clearly the
variable giving the greatest discrimination between
responders and non-responders, with F ratios more than
double those of the other variables. The transformations of
interval all gave better discrimination than the raw scale.
The biggest difference between the groups was shown by the
square root of interval and this variable was entered into the
discriminant function.
Having entered interval into the function, previous
response and type of second line treatment, which were
correlated with interval, were no longer significant. However,
FIGO stage remained highly significant and was able to
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Table I Characteristics of study group
Continuous variables
Median age (years)
Median interval (months)
Summary of other variables
Variable Groupb
treatment
Stage
Platinum based'
MD
CP/ABC
Mitoxantrone
Bleomycin/MMCd
Epirubicin/MMCd
I/II
III/IV
III
IV
Not known
Type Serous
Clear
Unspecified
Other
Mucinous
Endometroid
Undifferentiated
Differentiation Poor
Moderate/well
Moderate
Well
Unspecified
Best previous CR
response PR
Static/progression
Static
Progression
Adjuvant'
Previous DDP Yes
No
No. previous One
treatments Two or more
2
3
Responders Non-responders
59
21
54
3
Responders Non-responders
8
2
9
2
10
7
20
3
18
4
7
1
0
12
5
3
11
11
8
10
28
3
26
4
1
2
22
13
23
2
51
8
0
34
11
6
7
1
2
24
17
3
17
15
15
6
22
3
55
6
48
9
4
p
0.40a
<0.ooo1a
Total
9
4
31
15
33
9
71
11
1
52
15
13
8
1
3
36
22
6
28
26
23
7
23
13
83
9
74
13
x2 df. P
14.1 3 0.003
7.0e 1 0.008
4.3 3 0.23
0.02c 1 0.89
21.6 3 0.0001
o.oe 1 1.0
5 0.1 0.75
aMann-Whitney U test; bItalicised sub-groups were pooled for calculation ofX2; CMD=mitoxantrone/cis-platinum;
CP/ABC =cis-platinum/cyclophosphamide alternating with adriamycin/bleomycin/chlorambucil; dMMC =
mitomycin C; eAfter Yate's correction; 'Patients with no evaluable disease after primary surgery.
Table II Variables used in discriminant function analysis
Variable Forms tested in discriminant analysis
Age Age; age2; square root (age)
Interval Interval; square root (interval); log 10 (interval); ln(interval)
Alternative single cutpoints (of 12, 14, 16, 18, 20 months)
One variable with multiple cutpoints (1, 3, 6, 12, 18, 24 months)
Stage Stage I/TI vs. III/IV
Histology Serous vs. rest; clear vs. rest; unspecified vs. rest
Differentiation Poor vs. rest
Number of previous treatments One vs. rest
Best previous response CR/PR/Adjuvant vs. static/progression
Previous platinum chemotherapy No vs. yes
Type of drugs in phaseII study Platinum vs. rest; mitoxantrone vs. rest
improve the discrimination. When FIGO stage was entered,
none of the remaining variables could improve
discrimination between responders and non-responders.
The weights for interval and stage and constants derived
from the analysis were used to calculate the 'classification
scores' (S1 and S2) for each patient:
S= score for patient classification into responder group
--7.9 +8.9 x stage value + 1.7 x interval value
and
2 score for patient classification into non-responder group
= -6.9 + 11.6 x stage value+0.6 x interval value
where the stage value for patients with FIGO stage I or II at
presentation is 0 and with FIGO stage III or IV is 1; and the
interval is the square root of the interval from the end of
prior therapy to entering the phase II study in months.
Each of the patients was classified into the group for
which they had the highest score (Table III). The function
correctly classified 77.4% of patients who responded to
chemotherapy and 88.5% of those who did not, with 84.8%
being correctly classified overall.
Interval was by far the most important variable, and
although FIGO stage gave a statistically significant
improvement in discrimination between responders and non-
responders, it may not usefully improve the percentage652 G. BLACKLEDGE et al.
Table III Patient classifiction using scores SI and S2
Clinical observation
Classification Responded Did not respond
Responder 24 7
Non-responder 7 54
Predictive value of test (%) 77.4 88.5
Table IV Response rate using interval from previous treatment to
phaseII therapy only
Interval (months) Total no. No. responding % responding
<3 39 4 10
4-6 11 1 9
7-9 11 4 36
10-12 6 1 17
13-15 4 2 50
16-18 4 3 75
19-21 1 1 100
>21 16 15 94
Table V Classification of patients using alternative
single interval cutpoints
% correctly classified
Cutpoint
(months) Responders Progressors Overall
3 87.1 57.4 67.4
6 83.9 73.8 77.2
9 71.0 85.2 80.4
12 67.7 93.4 84.8
15 61.3 96.7 84.8
18 51.6 98.4 82.6
21 48.4 98.4 81.5
classified correctly. Therefore, the value of interval alone was
explored. A detailed breakdown of the relationship between
interval and response is given in Table IV. Although the
numbers in the sub-groups are small, these data suggest that
patients progressing on primary treatment, or relapsing
within 3-6 months of primary treatment have only a small
chance of responding. Patients with a remission duration of
greater than 15 months, however, stood a greater than 75%
chance of responding to treatment.
The effect of using interval alone on the ability to predict
responders and non-responders correctly is shown in Table
V, where the results for a range of cutpoints are given.
Adopting earlier cutpoints gives a better prediction of
responders at the expense of more progressing patients being
incorrectly classified as responders. When the latest cutpoint
(i.e. 21 months) is adopted, virtually all the progressors are
correctly identified at the expense of classifying responders
incorrectly as non-responders. A cutpoint of 12-15 months
gives the best overall classification of patients into
responders and non-responders. Using this cutpoint for
interval alone, the percentage of patients correctly classified
is as good as that achieved by the discriminant function.
Discussion
The evaluation of drugs for ovarian cancer in a phase II
setting is difficult. The undoubted efficacy of established
chemotherapy agents means that patients will be treated in
phase II studies when they have progressed or relapsed. In
addition, the patient population will be heterogeneous
showing a wide range of characteristics. The studies in this
analysis were chosen because the drugs had either shown
previous activity or because of evidence of in vitro activity.
This analysis demonstrates that there are other factors which
are of importance in determining whether a patient will
respond in a phase II study.
In the univariate analysis, interval between previous
therapy and entry to the phaseII study was significant, as
was the presenting stage of the patient, the second line
treatment chosen and the best previous response to therapy.
In the discriminant analysis, however, only two factors were
shown to be of importance, interval and the FIGO stage of
the patient. Using these two variables, the discriminant
analysis predicted 89% of those who did not respond and
75% of those who did, giving a correct prediction for 85%
of patients overall. The importance of interval is emphasised
by the observation that the response rate of those patients
who progressed on primary treatment and received phase II
therapy within 6 months of completing primary treatment
was very low (5/50 = 10%) (Table IV). Correspondingly,
those who had an interval of greater than 21 months
between previous therapy and phase II treatment had a high
response rate (19/21 = 90%). Indeed, in this study, it was
possible to classify correctly 85% of patients by using an
interval of 15 months or greater to predict those patients
who would respond. The cutpoint of 15 months correctly
predicted 61% of those who responded and 97% of those
who did not.
While this is a small study which needs replicating, two of
its findings are clear. Firstly, not all patients have the same
probability of responding to phase II treatments. Secondly,
even if future studies are able to improve the prediction of
response, interval between previous treatment and entry to
phaseII treatment is likely to remain of importance. These
observations have implications for the design of new phase II
studies and also for the clinical management of patients with
ovarian cancer relapsing from primary therapy.
The finding that not all patients have the same probability
of responding in phase II study leads to two problems:
1. The response rate achieved in a particular study will
depend not only on the efficacy of the agent being
used, but also on the proportion of patients entered
who have a very low probability of response.
2. The assumptions underlying the methods used to deter-
mine the required sample size for a phase II study may
be violated. Two studies with the same number of
patients would have a different chance of detecting an
active new agent if they had a different proportion of
patients with a low probability of response. This means
that phase II studies may be failing to detect active new
agents.
The entry criteria for phase II studies of new agents which
are likely to have activity similar to existing agents, should
exclude patients who have little chance of response. In
ovarian cancer, this could be achieved by excluding patients
who had progressed within 15 months of their previous
therapy or more simply by not considering patients for
phaseII studies who have failed primary therapy, or who
relapse within a few months. If it was thought that an agent
was genuinely novel then this very poor group of patients
might be used to identify agents with completely different
activity.
These observations relate primarily to the evaluation of
phase II treatments. The decision whether to treat a particu-
lar patient who has relapsed after primary therapy for
ovarian cancer must remain with the clinician. The obser-
vations of this study, however, give some indication of the
probability of response and may also influence the kind of
treatment given.
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